MRK241115C102000
- 0.01
- -0.01-50.00%
Merck & Co Newsroom
Trending Stocks This Week as Wall Street Sells off Amid Fed Remarks
U.S. Pharma Is Largely Immune From 'MAHA' Impact: Wolfe
The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business
We Think Merck's (NYSE:MRK) Robust Earnings Are Conservative
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
Vaccine Stocks Drop on Concerns About RFK Jr. Heading HHS
Want Dividend Safety, Consistency, Growth, and a Yield? See These 10 Names
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $148
Merck, Amgen Share Losses Lead Dow's 168-Point Drop
Jefferies Adjusts Price Target on Merck to $148 From $147, Maintains Buy Rating
Merck Keytruda Endorsed in EU for Rare Form of Cancer
Express News | Market news: Merck's Keytruda treatment for mesothelioma has received a positive evaluation from the European Union.
Top private equity funds in China expose the 'US stock report': the proportion of Chinese concept stocks continues to rise, with PDD Holdings and Apple being the focus of differences in components.
In the third quarter of this year, most Chinese private equity firms, such as Hillhouse, Gao Yi, and Jinglin, remained focused on Chinese concept stocks. However, Hillhouse and Jinglin chose to reduce their shareholding in pdd holdings, while Gao Yi opted to continue increasing its stake in pdd holdings.
Merck Says European Medicines Agency's Committee for Medicinal Products For Human Use Approves KEYTRUDA (Pembrolizumab), Anti-PD-1 Therapy, In Combination With Pemetrexed And Platinum Chemotherapy, For Adult Patients With Unresectable Non-epithelioid...
Express News | Merck Receives Positive EU Chmp Opinion for Keytruda® (Pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (Mpm)
Merck Receives Positive EU CHMP Opinion for KEYTRUDA (Pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)
Merck Initiated at Peer Perform by Wolfe Research
Merck & Co Analyst Ratings
The 'Trump trade' of the 2016 version completely reversed afterwards, what about this time?
After Trump's election victory, the US dollar, US stocks, and small cap stocks usually tend to strengthen. However, during Trump 1.0, from 2016 to 2020, the US dollar and small cap stocks performed poorly, failing to rise as expected, while the rise in US stocks was mostly attributable to the strength of technology stocks. Analysis suggests that the 'Trump trade' is not the same as 'Trump investment', it is more of a short-term market reaction rather than a long-term trend.
"How long can the Trump trade continue?"
Compared to other presidential candidates, the impact of Trump's victory is unique, but Wall Street should also be wary of the fading of this effect.